Imipenem/Cilastatin/Relebactam
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis, Pneumonia, Bacterial
Trial Timeline
Jan 3, 2023 → Dec 11, 2024
NCT ID
NCT05561764About Imipenem/Cilastatin/Relebactam
Imipenem/Cilastatin/Relebactam is a approved stage product being developed by Merck for Cystic Fibrosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05561764. Target conditions include Cystic Fibrosis, Pneumonia, Bacterial.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05561764 | Approved | Terminated |
Competing Products
20 competing products in Cystic Fibrosis